The National Institute for Clinical Excellence (NICE) has reversed its decision to recommend alendronate as the only osteoporosis treatment for post-menopausal women.
NICE have now issued a draft appraisal document recommending second-line use of risedronate and etidronate in primary and secondary prevention of fractures.
The decision comes after concerns that prmary care trusts were being forced to prescribe alendronate, when one in four patients cannot tolerate the drug.
David Reid, chairman of the National Osteoporosis Society medical board, said: "It is good news that NICE recognises that there is more than one drug out there for the treatment of osteoporosis, especially as many patients cannot tolerate alendronate.
NICE have also recommended strontium ranelate as an alternative treatment for women who cannot tolerate aledronate or risoedronate.
The Nursing in Practice Awards 2008will reward best practice in a variety of clinical areas. If you know someone who is quietly making hugestrides in but is not getting the recognition theydeserve, why not nominate them? Or maybe you were you involved in aninnovative, or introduced a new strategy or protocol in your practicethat improved service delivery? Tell us about it. For more information go to www.nursinginpractice.com/awards